Skip to main content

Table 1 Patient characteristics

From: Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer

Characteristic

N (%)

Age (years)

  ≤ 40

23(26.4%)

 41–50

27(31.1%)

  > 50

37(42.5%)

Histologic subtype

 No special type

85(97.7%)

 lobular

2(2.3%)

Tumor size (cm)

  ≤ 0.5

1(1.1%)

  > 0.5, ≤ 1

20(23.0%)

  > 1, ≤ 2

66(75.9%)

Histologic Grade

 1

17(19.6%)

 2

59(67.8%)

 3

11(12.6%)

Ki67

  ≤ 30%

16(18.4%)

  > 30%

71(81.6%)

P53

 Positive

25(28.7%)

 Negative

62(71.3%)

Basal-like marker

 Positive

12(13.8%)

 Negative

75(86.2%)

TILs

  ≤ 10%

65(74.7%)

 11–59%

19(21.8%)

  ≥ 60%

3(3.5%)

IHC surrogated subtype

 Luminal A

61(32.2%)

 Luminal B

26(67.8%)

Immune score

 Strong

43(49.4%)

 Weak

44(50.6%)

Chemotherapy

 Yes

26(29.9%)

 No

61(70.1%)

Endocrine therapy

 Yes

87(100%)

 No

0(0%)

Radiotherapy

 Yes

25(28.7%)

 No

62(71.3%)

Recurrent status

 Yes

26(29.9%)

 No

61(70.1%)

Distant metastasis

 Yes

15(17.2%)

 No

72(82.8%)

Living status

 Yes

84(96.6%)

 No

3(3.4%)